Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer

BACKGROUND: As a novel irreversible pan-ErbB inhibitor recently approved in China, pyrotinib has exhibited promising anticancer efficacy and acceptable safety profile in HER2-positive metastatic breast cancer (mBC). The aim of this retrospective study was to estimate the efficacy and safety of pyrot...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Ying, Chen, Beibei, Li, Jisheng, Peng, Ling, Li, Shuguang, Yu, Xuejun, Li, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449550/
https://www.ncbi.nlm.nih.gov/pubmed/34548820
http://dx.doi.org/10.2147/CMAR.S321428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449550/
https://www.ncbi.nlm.nih.gov/pubmed/34548820
http://dx.doi.org/10.2147/CMAR.S321428

Ejemplares similares